Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 217–240 of 310
Adipose Gene Therapy Cuts Chronic Disease Dosing Burden
Remedium Bio secured $10 million in Series A funding to advance a platform technology that converts subcutaneous fat tissue into sustained protein-production sites, reducing treatment frequency from multiple injections to single administrations with adjustable dosing. The approach targets cardiometabolic and chronic disease management through controlled gene expression.
Liver's dual protein-sensing pathways shift with age
Low-protein diets trigger distinct molecular responses in the liver during aging, mediated both through and independent of FGF21 signaling. This dual-pathway mechanism reveals how nutrient restriction at the transcriptomic level may influence metabolic adaptation and longevity outcomes across the lifespan.
The Immunogenicity of Human Senescent Cells Is Dependent on the Senescence Inducer and Cell Type
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
Gene therapy for aging advances to animal trials
Genflow Biosciences secured overwhelming shareholder approval for board leadership and capital authorization to advance its gene therapy pipeline targeting age-related diseases. The company is progressing GF-1002, its lead therapeutic candidate, through preclinical validation and early clinical evaluation in animal models with plans for human trials in metabolic disease.
Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK‐1/SIR‐2.1/DAF‐16 Signaling Axis in Caenorhabditis elegans
Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.
Gene therapy replaces repeated injections with single-dose adipocyte platform
Remedium Bio has secured $10 million in Series A funding to advance subcutaneous gene therapies designed to produce therapeutic proteins from fat tissue for multi-year duration with adjustable dosing. The platform targets replacement of repeated protein injections with single-administration gene therapy for cardiometabolic and chronic disease applications.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, regulates fast-cycling skin cell populations through the YAP signaling pathway. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of regenerative cell populations and compromised dermal-epidermal integrity, suggesting this protein may be central to maintaining skin renewal capacity across the lifespan.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, maintains populations of fast-cycling skin cells through YAP signaling. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of fast-cycling cells and compromised epidermal-dermal junction integrity, mirroring natural aging processes.
Autophagy Collapse Drives Sepsis Risk in Aging Kidneys
Aging kidneys show impaired autophagy activation—a cellular cleanup mechanism—making them vulnerable to sepsis-induced acute kidney injury. Restoring autophagy through TFEB activation or pharmacological intervention partially reverses this age-related deficit and protects against septic injury in aged tissues.
Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Pandorum Technologies raises $18M Series B to scale regenerative therapies
Pandorum Technologies secured $18 million in Series B funding to scale its programmable tissue engineering platform for wound healing and organ repair. The capital accelerates manufacturing, regulatory pathways, and clinical partnerships for regenerative therapies addressing tissue damage and loss.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Senescent Cells Define Aggressive Endometriosis Subtype
A correction to prior research clarifies the classification of an aggressive endometriosis subtype characterized by cellular senescence and immune modulation. The findings refine understanding of how aging-related cellular changes drive pathological remodeling in endometrial tissue, with implications for stratifying disease severity and treatment response.
Life Biosciences lands $80m to push cell reset therapy
Life Biosciences secured $80 million to advance ER-100, the first partial epigenetic reprogramming therapy entering human trials, designed to restore cellular function in age-damaged neurons. This represents a shift in aging intervention from symptom management toward addressing the underlying cellular decline that drives multiple age-related diseases.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
NK Cell Therapy Targets Immune Dysfunction in Neurodegeneration
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.
Cardiac Fibrosis Reversal: RNA Therapy Targets Aging Cell Behavior
HAYA Therapeutics received FDA Fast Track designation for HTX-001, an RNA-based therapy designed to reprogram fibroblasts and reverse cardiac fibrosis rather than manage heart disease symptoms. This regulatory milestone signals a shift toward cellular reprogramming as a mechanism for addressing age-related organ stiffening and dysfunction.
Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
Thymulin Restores Immune Function in Aging Cancer Models
Thymulin, a hormone produced by the thymus gland, reduces systemic inflammation in aging mice and enhances the effectiveness of cancer treatments. The research identifies thymulin as a circulating factor capable of modulating age-related immune dysfunction independently of full immune system rejuvenation.
Protein Aggregates Targeted in First Human Longevity Trial
Retro Biosciences, valued at $1.8 billion, has advanced an oral therapeutic into human trials that targets protein aggregate clearance—a mechanism implicated in Alzheimer's pathology. Early safety data show no dose-limiting toxicities, positioning the company to release efficacy findings in 2026 and marking a critical inflection from bench research to clinical validation in longevity therapeutics.
Ultrasound Gene Delivery Solves Repeat Treatment Problem
SonoThera's ultrasound-based gene delivery platform addresses a fundamental constraint in genetic medicine: the inability to repeat treatments and the size limitations of viral vectors. The technology uses microbubbles and targeted ultrasound to open cellular pathways without immune recognition, potentially enabling the repeated interventions required for aging-related therapies.
Why aging feels harder after 40
Circulating stem cell count declines sharply after age 30, reducing tissue repair capacity and resilience. This decline correlates with recovery time, injury healing, and disease risk—making stem cell abundance a measurable predictor of healthspan independent of conventional longevity markers.
KIF14 Loss Drives Egg Aging Through Energy Failure
Declining levels of the kinesin protein KIF14 impair egg cell quality during reproductive aging by disrupting both the cellular scaffold and mitochondrial function. This mechanism reveals a specific molecular pathway linking reproductive senescence to energy production failure, with direct implications for fertility outcomes across the reproductive lifespan.